公开(公告)号：US20160002269A1

公开(公告)日：2016-01-07

申请号：US14766996

申请日：2014-02-13

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Abraham SHANZER ,  Galina MELMAN ,  Yaniv BARDA ,  Raghavendra KIKKERI ,  Boris KRAIZ ,  Larissa GINAT

IPC: C07F5/00 ,  C09D11/38 ,  G01N21/64 ,  C09K11/06 ,  A61K49/10

CPC classification number: C07F5/003 ,  A61K49/106 ,  C09D11/38 ,  C09K11/06 ,  C09K2211/182 ,  G01N21/6428 ,  G01N21/6486 ,  G01N2021/6432

Abstract: The present invention is directed to multinuclear lanthanides chiral clusters, based on phenyl-oxazoline-amide (POxA) ligands, and to methods of use thereof. The chiral clusters of this invention are highly fluorescent with high stability.

Abstract translation: 本发明涉及基于苯基 - 恶唑啉 - 酰胺（POxA）配体的多核镧系元素手性簇及其使用方法。 本发明的手性簇是具有高稳定性的高度荧光。

公开(公告)号：US20160000909A1

公开(公告)日：2016-01-07

申请号：US14797894

申请日：2015-07-13

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal EISENBACH-SCHWARTZ ,  Kuti BARUCH ,  Neta ROSENZWEIG

IPC: A61K39/395 ,  A61K31/4155 ,  C07K16/28

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。

公开(公告)号：US09217041B2

公开(公告)日：2015-12-22

申请号：US14168024

申请日：2014-01-30

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Netta Sela-Paswell ,  Tamar Danon ,  Raanan Margalit

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/40 ,  C07K16/44

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K16/44 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.

Abstract translation: 公开了包含抗原识别区的抗体，其包含选自SEQ ID NO：4-15的6个CDR氨基酸序列。 还公开了其用途。

公开(公告)号：US20150362490A1

公开(公告)日：2015-12-17

申请号：US14754785

申请日：2015-06-30

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： David MARGULIES ,  Leila Motiei ,  Zohar Pode

IPC: G01N33/573 ,  C07K7/06

CPC classification number: G01N33/53 ,  C07D417/06 ,  C07D417/14 ,  C07F9/6541 ,  C07K7/06 ,  C09K11/06 ,  C09K2211/1029 ,  C09K2211/1037 ,  G01N33/573 ,  G01N33/574 ,  G01N33/582 ,  G01N2333/91177 ,  G01N2333/918 ,  G01N2333/96494

Abstract: The present invention is directed to fluorescent protein biosensors based on oligonucleotide cross reactive sensor arrays including a selective and a non-selective protein surface binding domain for protein detection. Interaction of different protein isoforms with the sensors of this invention yields a unique optical signature for each protein. The unique optical signature allows differentiating between closely related protein isoforms and diagnosing diseases and disorders associated with the proteins also in biofluids.

Abstract translation: 本发明涉及基于寡核苷酸交叉反应性传感器阵列的荧光蛋白生物传感器，其包括用于蛋白质检测的选择性和非选择性蛋白质表面结合结构域。 不同蛋白质同种型与本发明传感器的相互作用产生了每种蛋白质独特的光学特征。 独特的光学特征允许区分密切相关的蛋白质同种型，并在生物流体中诊断与蛋白质相关的疾病和病症。

公开(公告)号：US20150307883A1

公开(公告)日：2015-10-29

申请号：US14439248

申请日：2013-10-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Michael SELA ,  Georg MAHLKNECHT ,  Ruth MARON ,  Bilha SCHECHTER

IPC: C12N15/115 ,  G01N33/574

CPC classification number: C12N15/115 ,  A61K31/7088 ,  C12N2310/16 ,  C12N2310/351 ,  C12N2310/3517 ,  C12N2310/51 ,  C12N2320/13 ,  C12N2320/30 ,  C12N2330/30 ,  G01N33/57492 ,  G01N2333/91205

Abstract: Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

Abstract translation: 提供了单体和多聚体适体。 还提供了包含其的药物组合物和使用它们的方法。

公开(公告)号：US09145559B2

公开(公告)日：2015-09-29

申请号：US14354580

申请日：2012-10-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Shaul ,  Peter Tsvetkov ,  Julia Adler

IPC: A61K48/00 ,  C12N15/113 ,  A61K31/713 ,  C12Q1/02 ,  C12Q1/68

CPC classification number: C12N15/1137 ,  A61K31/713 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/025 ,  C12Q1/68 ,  G01N33/5011 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.

Abstract translation: 公开了一种治疗癌症的方法。 该方法包括向受试者施用治疗有效量的药物组合物，其包含诱导26S蛋白酶体复合体解离成20S组分和19S组分从而抑制26S蛋白酶体活性的试剂，其中所述药剂没有 化疗剂。

公开(公告)号：US20150209404A1

公开(公告)日：2015-07-30

申请号：US14677123

申请日：2015-04-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal EISENBACH-SCHWARTZ ,  Ester YOLES ,  Hadas SCHORI

IPC: A61K38/07 ,  G01N33/569 ,  A61K31/4985 ,  A61K31/53 ,  A61K31/7068 ,  A61K31/519

CPC classification number: A61K38/07 ,  A61K31/00 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/53 ,  A61K31/7068 ,  A61K35/15 ,  A61K45/00 ,  A61K45/06 ,  G01N33/56972 ,  G01N33/6896 ,  G01N2333/70553 ,  G01N2333/70596 ,  G01N2800/28 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

Abstract translation: 本发明提供了用于早期诊断肌萎缩性侧索硬化（ALS）并用于确定ALS患者中ALS治疗的功效的方法，即利用细胞血液标志物监测ALS进展; 以及执行这些方法的工具包。

公开(公告)号：US20150144498A1

公开(公告)日：2015-05-28

申请号：US14409144

申请日：2013-06-25

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： David Scheiner ,  Jacob Karni ,  Raymond A George ,  Gabriel Seiden

IPC: C25B15/00 ,  C25B9/18

CPC classification number: C25B15/00 ,  B01J8/067 ,  B01J19/248 ,  B01J2219/00078 ,  B01J2219/00081 ,  B01J2219/00085 ,  B01J2219/00135 ,  B01J2219/00155 ,  B01J2219/00186 ,  C25B9/00 ,  C25B9/18 ,  F28D7/06 ,  F28D7/106 ,  F28D7/12 ,  F28F21/04

Abstract: A reactor is provided which comprises: a plurality of reaction units located within a reaction zone, each of the reaction units being adapted to enable carrying out a chemical reaction of one or more raw gases (e.g. at least one of CO2 and H20); ingress means to allow introduction of the one or more raw gases into the reaction zone and to allow distributing the incoming gas to the plurality of reaction units; egress means to allow exit of reaction products from the reaction zone; and a heating system. The reaction units extend essentially along a longitudinal axis of the reaction zone and are arranged in a spaced-apart relationship along a lateral axis of the reaction zone. The heating system comprises a plurality of heating sources extending along the reaction zone, thereby providing at least a part of the energy to carry out the reaction process within the reaction units.

Abstract translation: 提供了一种反应器，其包括：位于反应区内的多个反应单元，每个反应单元适于使得能够进行一种或多种原料气体（例如CO 2和H 2 O中的至少一种）的化学反应; 入口装置允许将一种或多种原料气体引入反应区并允许将进入的气体分配到多个反应单元; 出口意味着允许反应产物从反应区排出; 和加热系统。 反应单元基本上沿着反应区的纵向轴线延伸，并沿着反应区域的横向轴线以间隔的关系排列。 加热系统包括沿着反应区延伸的多个加热源，从而提供至少一部分能量以在反应单元内进行反应过程。

公开(公告)号：US20150110786A1

公开(公告)日：2015-04-23

申请号：US14383571

申请日：2013-03-07

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Deborah Fass ,  Iris Grossman ,  Tal Ilani ,  Assaf Alon

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y108/03002

Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.

Abstract translation: 公开了抑制或预防基底膜中层粘连蛋白组合的方法。 该方法包括使组织与抑制QSOX1活性或表达的试剂接触，由此抑制或预防基底膜中的层粘连蛋白的组装。

公开(公告)号：US20150056216A1

公开(公告)日：2015-02-26

申请号：US14536754

申请日：2014-11-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： MICHAEL SELA ,  YOSEF YARDEN ,  BILHA SCHECHTER ,  TSIPI BEN-KASUS

IPC: A61K39/395

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/565

Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

Abstract translation: 提供了鉴定具有组合改善的抗肿瘤活性的抗体组合的方法。 该方法包括：（a）鉴定抗ErbB-2抗体的结合表位; 和（b）选择表现出与ErbB-2上不同表位结合的抗ErbB-2抗体的至少两种抗体的组合，至少一种不同表位位于ErbB-2的二聚位点， 抗体与组合的改善的抗肿瘤活性的组合。 还提供了根据本发明揭示的新型抗体组合。